(S,S,S)-N-Fluorenylmethyloxycarbonyl-2-azabicyclo[3.3.0]octane-3-carboxylic acid | 130309-34-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (S,S,S)-N-Fluorenylmethyloxycarbonyl-2-azabicyclo[3.3.0]octane-3-carboxylic acid
• 英文别名: (2S,3aS,6aS)-1-{[(9H-Fluoren-9-yl)methoxy]carbonyl}octahydrocyclopenta[b]pyrrole-2-carboxylic acid；Fmoc-Thi-OH；(2S,3aS,6aS)-1-(((9H-fluoren-9-yl)methoxy)carbonyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid；(2S,3aS,6aS)-1-(9H-fluoren-9-ylmethoxycarbonyl)-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
• CAS: 130309-34-1
• 化学式: C₂₃H₂₃NO₄
• 分子量: 377.44
• InChiKey: XPFJHPFCCQQAJH-WVFSVQOHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S,S,S)-N-Fluorenylmethyloxycarbonyl-2-azabicyclo[3.3.0]octane-3-carboxylic acid 在 盐酸 、 WSCD*HCl 、 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 二乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 H-Val-Aoc-Met-OMe
  参考文献：
  名称：

  Synthesis and biological activity of pseudopeptides inhibitors of Ras farnesyl transferase containing unconventional amino acids

  摘要：

  A study was performed on the structure-activity relationships of a series of phenol derivatives, CVFM analogs, derived from the two most active compounds of a first series (1(A) and 1(B)) of inhibitors of Ras farnesyl transferase (FTase) that we have recently described. We report the synthesis and the activity of a second series of compounds in which the phenylalanine residue was replaced by unconventional aromatic and non-aromatic amino acids, with varying electronic, lipophilic, steric and conformational properties. The compounds showed to be significantly less active than reference compounds against FT, with the only exception of derivative 3(A) (IC50 = 3 mu M), which is slightly more active than 1(A) but not 1(B). Subsequently we tested the effects of compounds 1(A), 1(B) and 3(A), 3(B) on the anchorage-dependent growth of two epithelial cell lines of rats, FRTL-5 and the same line v-aa-ras transformed. Compound 3, derived from lead compound 1(A), showed an appreciable selectivity against transformed cells. In contrast, compounds derived from derivative 1(B) had only a modest cellular activity. (C) 1999 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(99)00104-4
• 作为产物：
  描述：

  1-(9H-fluoren-9-yl)methyl 2-benzyl (2S,3aS,6aS)-hexahydro-cyclopenta[b]pyrrole-1,2(2H)-dicarboxylate 在 palladium 10% on activated carbon 环己烯 作用下， 以 乙醇 为溶剂， 反应 7.0h， 以37%的产率得到(S,S,S)-N-Fluorenylmethyloxycarbonyl-2-azabicyclo[3.3.0]octane-3-carboxylic acid
  参考文献：
  名称：

  WO2008/95841

  摘要：

  公开号：

文献信息

• [EN] MASP INHIBITORY COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE MASP ET LEURS UTILISATIONS
  申请人：BAYER AG

  公开号：WO2020225095A1

  公开（公告）日：2020-11-12

  The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

  本发明涉及新型甘霖结合凝集素（MBL）相关丝氨酸蛋白酶（MASP）抑制化合物，以及其类似物和衍生物，以及其制备方法，单独或组合用于治疗和/或预防疾病，以及用于生产药物治疗和/或预防疾病，特别是用于治疗和/或预防肾脏和心血管疾病以及缺血再灌注损伤。
• NITRIC OXIDE DONOR COMPOUNDS
  申请人：Almirante Nicoletta

  公开号：US20100099729A1

  公开（公告）日：2010-04-22

  The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolismsdysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.

  本发明涉及一种一氧化氮供体化合物及其在治疗心血管疾病、炎症、疼痛、发热、胃肠道疾病、眼科疾病、肝脏疾病、肾脏疾病、呼吸系统疾病、免疫系统疾病、骨代谢功能障碍、中枢神经系统和周围神经系统疾病、性功能障碍、感染性疾病、抑制血小板聚集和血小板粘附、治疗由异常细胞增殖引起的病理性状况以及血管疾病方面的应用。该发明还涉及包含本发明中至少一种一氧化氮释放化合物的组合物，以及包含本发明中至少一种一氧化氮释放化合物和至少一种治疗剂的组合物。
• Nitric oxide donor compounds
  申请人：NICOX S.A.

  公开号：US09266820B2

  公开（公告）日：2016-02-23

  The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metabolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.

  本发明涉及一种硝酸盐供体化合物及其用于治疗心血管疾病、炎症、疼痛、发热、胃肠道疾病、眼科疾病、肝脏疾病、肾脏疾病、呼吸系统疾病、免疫系统疾病、骨代谢紊乱、中枢和外周神经系统疾病、性功能障碍、感染性疾病、用于抑制血小板聚集和血小板粘附、用于治疗由异常细胞增殖引起的病理状况的组合物。本发明还涉及包含本发明中至少一种硝酸盐释放化合物的组合物以及包含本发明中至少一种硝酸盐释放化合物和至少一种治疗剂的组合物。
• [EN] COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES DU POUMON
  申请人：RADIKAL THERAPEUTICS INC

  公开号：WO2013190497A3

  公开（公告）日：2014-03-13
• COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG
  申请人：RADIKAL THERAPEUTICS INS.

  公开号：US20150368197A1

  公开（公告）日：2015-12-24

  Pharmaceutical compositions and methods are for treatment of an inflammatory disease of the lung caused by inhalation of a toxic agent or an irritant. In one example, chlorine inhalational lung injury can be treated using compounds useful in such compositions.